822 related articles for article (PubMed ID: 23684423)
1. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity.
Vincent FB; Saulep-Easton D; Figgett WA; Fairfax KA; Mackay F
Cytokine Growth Factor Rev; 2013 Jun; 24(3):203-15. PubMed ID: 23684423
[TBL] [Abstract][Full Text] [Related]
2. BAFF-R and TACI expression on CD3+ T cells: Interplay among BAFF, APRIL and T helper cytokines profile in systemic lupus erythematosus.
Salazar-Camarena DC; Ortíz-Lazareno P; Marín-Rosales M; Cruz A; Muñoz-Valle F; Tapia-Llanos R; Orozco-Barocio G; Machado-Contreras R; Palafox-Sánchez CA
Cytokine; 2019 Feb; 114():115-127. PubMed ID: 30467093
[TBL] [Abstract][Full Text] [Related]
3. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases.
Samy E; Wax S; Huard B; Hess H; Schneider P
Int Rev Immunol; 2017 Jan; 36(1):3-19. PubMed ID: 28215100
[TBL] [Abstract][Full Text] [Related]
4. Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus.
Salazar-Camarena DC; Ortiz-Lazareno PC; Cruz A; Oregon-Romero E; Machado-Contreras JR; Muñoz-Valle JF; Orozco-López M; Marín-Rosales M; Palafox-Sánchez CA
Lupus; 2016 May; 25(6):582-92. PubMed ID: 26424128
[TBL] [Abstract][Full Text] [Related]
5. A mouse model of systemic lupus erythematosus responds better to soluble TACI than to soluble BAFFR, correlating with depletion of plasma cells.
Haselmayer P; Vigolo M; Nys J; Schneider P; Hess H
Eur J Immunol; 2017 Jun; 47(6):1075-1085. PubMed ID: 28383107
[TBL] [Abstract][Full Text] [Related]
6. Expressions of BAFF/BAFF receptors and their correlation with disease activity in Chinese SLE patients.
Zhao LD; Li Y; Smith MF; Wang JS; Zhang W; Tang FL; Tian XP; Wang HY; Zhang FC; Ba DN; He W; Zhang X
Lupus; 2010 Nov; 19(13):1534-49. PubMed ID: 20974656
[TBL] [Abstract][Full Text] [Related]
7. [BAFF/APRIL pathway in Sjögren syndrome and systemic lupus erythematosus: relationship with chronic inflammation and disease activity].
Vadacca M; Margiotta D; Sambataro D; Buzzulini F; Lo Vullo M; Rigon A; Afeltra A
Reumatismo; 2010; 62(4):259-65. PubMed ID: 21253619
[TBL] [Abstract][Full Text] [Related]
8. The BAFF/APRIL system in SLE pathogenesis.
Vincent FB; Morand EF; Schneider P; Mackay F
Nat Rev Rheumatol; 2014 Jun; 10(6):365-73. PubMed ID: 24614588
[TBL] [Abstract][Full Text] [Related]
9. BAFF, APRIL and their receptors: structure, function and signaling.
Bossen C; Schneider P
Semin Immunol; 2006 Oct; 18(5):263-75. PubMed ID: 16914324
[TBL] [Abstract][Full Text] [Related]
10. Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production.
Morimoto S; Nakano S; Watanabe T; Tamayama Y; Mitsuo A; Nakiri Y; Suzuki J; Nozawa K; Amano H; Tokano Y; Kobata T; Takasaki Y
Rheumatology (Oxford); 2007 Jul; 46(7):1083-6. PubMed ID: 17500077
[TBL] [Abstract][Full Text] [Related]
11. TACI deletion protects against progressive murine lupus nephritis induced by BAFF overexpression.
Arkatkar T; Jacobs HM; Du SW; Li QZ; Hudkins KL; Alpers CE; Rawlings DJ; Jackson SW
Kidney Int; 2018 Oct; 94(4):728-740. PubMed ID: 29907458
[TBL] [Abstract][Full Text] [Related]
12. BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway.
Endo T; Nishio M; Enzler T; Cottam HB; Fukuda T; James DF; Karin M; Kipps TJ
Blood; 2007 Jan; 109(2):703-10. PubMed ID: 16973958
[TBL] [Abstract][Full Text] [Related]
13. TACI haploinsufficiency protects against BAFF-driven humoral autoimmunity in mice.
Jacobs HM; Arkatkar T; Du SW; Scharping NE; Woods J; Li QZ; Hudkins KL; Alpers CE; Rawlings DJ; Jackson SW
Eur J Immunol; 2021 Sep; 51(9):2225-2236. PubMed ID: 34146342
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms in genes of the BAFF/APRIL system may constitute risk factors of B-CLL--a preliminary study on a Polish population.
Jasek M; Wagner M; Sobczynski M; Wolowiec D; Kuliczkowski K; Woszczyk D; Kielbinski M; Kusnierczyk P; Frydecka I; Karabon L
Tissue Antigens; 2015 Oct; 86(4):279-84. PubMed ID: 26268376
[TBL] [Abstract][Full Text] [Related]
15. Deleting the BAFF receptor TACI protects against systemic lupus erythematosus without extensive reduction of B cell numbers.
Figgett WA; Deliyanti D; Fairfax KA; Quah PS; Wilkinson-Berka JL; Mackay F
J Autoimmun; 2015 Jul; 61():9-16. PubMed ID: 26027434
[TBL] [Abstract][Full Text] [Related]
16. B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin.
Dillon SR; Harder B; Lewis KB; Moore MD; Liu H; Bukowski TR; Hamacher NB; Lantry MM; Maurer M; Krejsa CM; Ellsworth JL; Pederson S; Elkon KB; Wener MH; Dall'Era M; Gross JA
Arthritis Res Ther; 2010; 12(2):R48. PubMed ID: 20302641
[TBL] [Abstract][Full Text] [Related]
17. TACI, an enigmatic BAFF/APRIL receptor, with new unappreciated biochemical and biological properties.
Mackay F; Schneider P
Cytokine Growth Factor Rev; 2008; 19(3-4):263-76. PubMed ID: 18514565
[TBL] [Abstract][Full Text] [Related]
18. The rationale for BAFF inhibition in systemic lupus erythematosus.
Davidson A
Curr Rheumatol Rep; 2012 Aug; 14(4):295-302. PubMed ID: 22535567
[TBL] [Abstract][Full Text] [Related]
19. Similarities and differences between selective and nonselective BAFF blockade in murine SLE.
Ramanujam M; Wang X; Huang W; Liu Z; Schiffer L; Tao H; Frank D; Rice J; Diamond B; Yu KO; Porcelli S; Davidson A
J Clin Invest; 2006 Mar; 116(3):724-34. PubMed ID: 16485042
[TBL] [Abstract][Full Text] [Related]
20. The role of the BAFF/APRIL system in the T cell-independent specific response to blood stage Plasmodium falciparum hemozoin.
Dechkajorn W; Benjathummarak S; Kumsiri R; Maneerat Y
Cytokine; 2018 Nov; 111():445-453. PubMed ID: 29884307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
